Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL27821286 | 1.00 | LMNA (0.58) | LMNAKDM4EL3MBTL1MAPTAOC3 | |
| SCHEMBL1154790 | 1.00 | LMNA (0.58) | LMNAKDM4EL3MBTL1MAPTAOC3 | |
| SCHEMBL4416648 | 1.00 | LMNA (0.58) | LMNAKDM4EL3MBTL1MAPTAOC3 | |
| SCHEMBL12222364 | 0.86 | LMNA (0.48) | LMNAKDM4EL3MBTL1MAPTAOC3 | |
| SCHEMBL14758666 | 0.83 | RIPK1 (0.55) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| SCHEMBL1779384 | 0.83 | RIPK1 (0.55) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| SCHEMBL4426990 | 0.81 | LMNA (0.56) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| SCHEMBL5609841 | 0.81 | RIPK1 (0.53) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| SCHEMBL18530454 | 0.80 | LMNA (0.43) | LMNAKDM4EL3MBTL1MAPTAOC3 | |
| SCHEMBL8257890 | 0.80 | ALDH1A1 (0.49) | LMNAKDM4EMAPTAOC3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509417-B2 | Enantioselective process | SYNGENTA CROP PROTECTION AG (CH) | 2025-12-30 | — | — | US | disclosed |
| CN-113195460-B | Enantioselective process | 先正达农作物保护股份公司 | 2024-07-19 | — | — | CN | disclosed |
| US-20230331737-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2023-10-19 | — | — | US | disclosed |
| EP-3877372-B1 | ENANTIOSELECTIVE REDUCTION OF OXIME-DERIVATIVES INVOLVING IRIDIUM BASED CATALYSTS | SYNGENTA CROP PROTECTION AG (CH) | 2023-08-02 | — | — | EP | disclosed |
| US-20220106263-A1 | ENANTIOSELECTIVE PROCESS | SYNGENTA CROP PROTECTION AG (CH) | 2022-04-07 | — | — | US | disclosed |
| US-11230557-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| EP-3877372-A1 | ENANTIOSELECTIVE PROCESS | Syngenta Crop Protection AG (CH) | 2021-09-15 | — | — | EP | disclosed |
| CN-113195460-A | Enantioselective process | 先正达农作物保护股份公司 | 2021-07-30 | — | — | CN | disclosed |
| US-11021492-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210008041-A1 | MTORC MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2021-01-14 | — | — | US | disclosed |
| US-20080228008-A1 | Substituted Cyclohexanones | FIRMENICH SA (CH) | 2008-09-18 | — | — | US | disclosed |
| US-20080228008-A1 | Substituted Cyclohexanones | FIRMENICH SA (CH) | 2008-09-18 | — | — | US | disclosed |
| US-7332633-B2 | Process for the preparation of optically active cyclohexenones | FIRMENICH SA (CH) | 2008-02-19 | — | — | US | disclosed |
| US-7332633-B2 | Process for the preparation of optically active cyclohexenones | FIRMENICH SA (CH) | 2008-02-19 | — | — | US | disclosed |
| WO-2007010483-A1 | SUBSTITUTED CYCLOHEXANONES | FIRMENICH SA (CH) | 2007-01-25 | — | — | WO | disclosed |
| WO-2004106269-A1 | METHOD FOR PRODUCING SUBSTITUTED SHIRAL DIOLS AND DIOL-ANALOGOUS DERIVATIVES | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2004-12-09 | — | — | WO | disclosed |
| US-20030171544-A1 | Alcohol dehydrogenase and use thereof | DEGUSSA AG (DE) | 2003-09-11 | — | — | US | disclosed |
| US-20030045727-A1 | Process for preparing optically active secondary alcohols having nitrogenous or oxygenic functional groups | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2003-03-06 | — | — | US | disclosed |
| EP-1254885-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE SECONDARY ALCOHOLS HAVING NITROGENOUS OR OXYGENIC FUNCTIONAL GROUPS | Asahi Kasei Kabushiki Kaisha (JP) | 2002-11-06 | — | — | EP | disclosed |
| EP-1241263-A1 | Alcohol dehydrogenase and uses therefor | Degussa AG (DE) | 2002-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509417-B2 | Enantioselective process | HCCS, AOC3, CYP8B1 | LMNA 1672/4885KDM4E 2012/4885L3MBTL1 1082/4885 |
| US-20220106263-A1 | ENANTIOSELECTIVE PROCESS | CYP11B2, CYP2E1, CYP2F1 | LMNA 4787/4885KDM4E 576/4885L3MBTL1 4624/4885 |
| US-20210008041-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | LMNA 4444/4885KDM4E 1617/4885L3MBTL1 1721/4885 |
| US-11230557-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | LMNA 4444/4885KDM4E 1617/4885L3MBTL1 1721/4885 |
| US-20230331737-A1 | MTORC1 MODULATORS AND USES THEREOF | MTOR, RPTOR, RICTOR | LMNA 4711/4885KDM4E 1611/4885L3MBTL1 694/4885 |
| US-20030171544-A1 | Alcohol dehydrogenase and use thereof | ADH5, ADH1A, ADH1C | LMNA 4722/4885KDM4E 2461/4885L3MBTL1 2989/4885 |
| US-20080228008-A1 | Substituted Cyclohexanones | NQO1, CYP2J2, CBR3 | LMNA 1007/4885KDM4E 1219/4885L3MBTL1 4821/4885 |
| US-20030045727-A1 | Process for preparing optically active secondary alcohols having nitrogenous or oxygenic functional groups | ADH1A, ADH5, ADH1C | LMNA 3712/4885KDM4E 3774/4885L3MBTL1 4559/4885 |
| US-11021492-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | LMNA 4444/4885KDM4E 1617/4885L3MBTL1 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.